JJP Biologics has received a positive conclusion on the Clinical Trial Application assessment for a Phase I Study of a potential first-in-class anti-CD89 antagonist, JJP-1212 monoclonal antibody for
JJP Biologics a private biopharmaceutical company developing innovative antibodybased therapies announces a positive decision issued by the European Medicines Agency on the Clinical Trial Application to conduct a phase I clinical study in healthy participants EudraCT 20235086613300 with their potential firstinclass antiCD89 antagonist JJP1212.
The FDA granted priority review to inavolisib plus palbociclib/fulvestrant for HR-positive, HER2-negative, advanced breast cancer with PIK3CA mutations.
- Plozasiran significantly lowered triglyceride levels with commensurate reductions in APOC3, non-HDL-C, and remnant cholesterol
- Data presented at European Atherosclerosis Society 92nd Congress.
- Review of European marketing application for PKU now initiated -
WARREN, N.J., May 28, 2024 /PRNewswire/ PTC Therapeutics, Inc. announced today that the sepiapterin MAA for PKU has been.